VIPoma.
Helbing A, Menon G, Sandhu S, Jialal I.
2025 Feb 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Vasoactive intestinal peptide secreting tumour: An overview.
Una Cidon E.
World J Gastrointest Oncol. 2022 Apr 15;14(4):808-819. doi: 10.4251/wjgo.v14.i4.808.
Pancreatic neuroendocrine tumors.
Batcher E, Madaj P, Gianoukakis AG.
Endocr Res. 2011;36(1):35-43. doi: 10.3109/07435800.2010.525085.
Chronic Diarrhea Caused by Vasoactive Intestinal Peptide-Secreting Tumor.
Belei O, Basaca DG, Heredea ER, Iacob ER, Olariu L, Folescu R, Motoc AGM, Nanu AM, Mărginean O.
Life (Basel). 2023 Sep 27;13(10):1974. doi: 10.3390/life13101974.
Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.
Battershill PE, Clissold SP.
Drugs. 1989 Nov;38(5):658-702. doi: 10.2165/00003495-198938050-00002.
A calcitonin and vasoactive intestinal peptide-producing pancreatic endocrine tumor associated with the WDHA syndrome.
Ichimura T, Kondo S, Okushiba S, Morikawa T, Katoh H.
Int J Gastrointest Cancer. 2003;33(2-3):99-102. doi: 10.1385/IJGC:33:2-3:99.
Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review.
Schizas D, Mastoraki A, Bagias G, Patras R, Moris D, Lazaridis II, Arkadopoulos N, Felekouras E.
J BUON. 2019 Mar-Apr;24(2):415-423.
Endocrine neoplasms (non-gastrin) of the pancreas.
Gower WR Jr, Fabri PJ.
Semin Surg Oncol. 1990;6(2):98-109. doi: 10.1002/ssu.2980060208.
Cyclical release of vasoactive intestinal polypeptide (VIP) from a pancreatic islet cell apudoma.
Devine BL, Carmichael HA, Russell RI, Joffe SN.
Postgrad Med J. 1978 Aug;54(634):566-70. doi: 10.1136/pgmj.54.634.566.
Mixed pancreatic apudoma with symptoms of excess vasoactive intestinal polypeptide and insulin: improvement of diarrhoea with metoclopramide.
Long RG, Bryant MG, Yuille PM, Polak JM, Bloom SR.
Gut. 1981 Jun;22(6):505-11. doi: 10.1136/gut.22.6.505.
